Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A Case–Control Study

Katherine Juba
St. John Fisher University, kjuba@sjf.edu

Tina M. Khadem
University of Rochester Medical Center

David Hutchinson
St. John Fisher University, dhutchinson@sjfc.edu

Jack Brown
St. John Fisher University

Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A Case–Control Study

Abstract

Background: Methadone (ME) is commonly used in pain and palliative care (PPC) patients with refractory pain or intolerable opioid adverse effects (AEs). A unique ME AE is its corrected QT (QTc) interval prolongation risk, but most evidence exists in methadone maintenance therapy patients.

Objective: Our goal was to identify QTc interval prolongation risk factors in PPC patients receiving ME and other medications known to prolong the QTc interval and develop a risk stratification tool.

Design: We performed a case–control study of adult inpatients receiving ME for pain management.

Settings/Subjects: Adult inpatients receiving ME with a QTc >470 msec (males) and >480 msec (females) were matched 1:2 according to age, history of QTc prolongation, and gender with ME patients who did not have a prolonged QTc interval. QTc prolongation risk factors were collected for both groups. Covariates were analyzed using conditional logistic regression. Classification and regression tree analysis was used to identify the ME dose associated with QTc prolongation.

Results: Predictors of QTc prolongation included congestive heart failure (CHF) (OR: 11.9; 95% CI: 3.7–38.2; $p < 0.00$), peptic ulcer disease (PUD) (odds ratio [OR]: 8.3; 95% confidence interval [95% CI]: 2.4–28.9; $p < 0.00$), hypokalemia (OR: 6.5; 95% CI: 1.5–28.2; $p < 0.01$), rheumatologic diseases (OR: 4.7; 95% CI: 1.6–13.9; $p < 0.00$), taking medications with a known torsades de pointes (TdP) risk (OR: 4.4; 95% CI: 1.8–10.7; $p < 0.01$), malignancy (OR: 3.3; 95% CI: 1.2–9.3; $p < 0.03$), hypocalcemia (OR: 2.1; 95% CI: 0.9–4.8; $p < 0.07$), and ME doses >45 mg per day (OR: 1.9; 95% CI: 0.8–4.8; $p < 0.16$). Mild liver disease was protective against QTc prolongation (OR: 0.05; 95% CI: 0.0–0.46; $p < 0.01$).

Conclusions: Predictors of QTc prolongation in our multivariate conditional logistic regression model included CHF, PUD, hypokalemia, rheumatologic disorders, use of medications with a known TdP risk, malignancy, hypocalcemia, and ME doses >45 mg per day.

Abstract:

Background: Methadone (ME) is commonly used in pain and palliative care (PPC) patients with refractory pain or intolerable opioid adverse effects (AEs). A unique ME AE is its QTc interval prolongation risk but most evidence exists in methadone maintenance therapy) patients.

Objective: Our goal was to identify QTc interval prolongation risk factors in PPC patients receiving ME and other medications known to prolong the QTc interval and develop a risk stratification tool.

Design: We performed a case control study of adult inpatients receiving ME for pain management.

Settings/Subjects: Adult inpatients receiving ME with a QTc > 470 msec (males) and > 480 msec (females) were matched 1:2 according to age, history of QTc prolongation, and gender with ME patients who did not have a prolonged QTc interval.

Measurements: QTc prolongation risk factors were collected for both groups.   Covariates were analyzed using conditional logistic regression. Classification and regression tree analysis was used to identify the ME dose associated with QTc prolongation.

Results: Predictors of QTc prolongation included congestive heart failure (CHF) (OR: 11.9; 95% CI: 3.7-38.2; p<0.00), peptic ulcer disease (PUD) (OR: 8.3; 95% CI: 2.4-28.9; p<0.00), hypokalemia (OR: 6.5; 95% CI: 1.5-28.2; p<0.01), rheumatologic diseases (OR: 4.7; 95% CI: 1.6-13.9; p<0.00), taking medications with a known torsades de pointes risk (OR: 4.4; 95% CI: 1.8-10.7; p<0.01), malignancy (OR: 3.3; 95% CI: 1.2-9.3; p<0.03), hypocalcemia (OR: 2.1; 95% CI: 0.9-4.8; p<0.07), and ME doses > 45mg/day (OR: 1.9; 95% CI: 0.8-4.8; p<0.16). Mild liver disease was protective against QTc prolongation (OR: 0.05; 95% CI: 0.0-0.46; p<0.01).

Conclusion: Predictors of QTc prolongation in our multivariate conditional logistic regression model included CHF, PUD, hypokalemia, rheumatologic disorders, use of medications with a known TdP risk, malignancy, hypocalcemia, and ME doses > 45mg/day.

Introduction:

Methadone is a synthetic opioid that is a μ and δ receptor agonist, N-methyl-D-aspartate (NDMA) receptor antagonist, and inhibits reuptake of serotonin and norepinephrine.[1-4] Its use for pain and palliative care (PPC) patients who have a poor response to previous opioid regimens or experience intolerable opioid adverse effects has increased methadone's prescribing frequency. A unique methadone adverse effect (AE) compared to other opioid agonists is its risk of prolonging the corrected QT (QTc) interval which serves as a surrogate marker for predicting torsades de pointes (TdP) or sudden cardiac death.[5] Since 2000 methadone is the second most commonly reported drug causing QTc prolongation or TdP in the US Food and Drug Administration Adverse Event Reporting System (FDA AERS).[6] However, most of the evidence for methadone induced QTc prolongation is in methadone maintenance therapy (MMT) patients, not chronic pain or more medically fragile palliative care patients. The risk of QTc prolongation is increased in patients with electrolyte disturbances, structural heart disease, bradycardia, female sex, advanced age, a history of QTc prolongation, concurrent use of other QTc prolonging medications, and drug interactions that increase serum concentrations of QTc prolonging drugs.[7] The majority of drug-induced QTc prolongation cases occur when patients have at least one additional risk factor.[8] It is common practice for palliative care and chronic pain patients to have several risk factors, especially the use of multiple drugs known to prolong QTc or decrease methadone clearance. A limitation in the current literature is the dearth of studies assessing the additive effect of QTc prolongation from the use of multiple QTc prolonging medications and/or drugs that inhibit methadone metabolism on QTc prolongation. This lack of understanding about the potential clinical harms when methadone is combined with interacting medications was identified as a research gap in a recent review.[9] Our goal was to identify QTc interval prolongation risk factors in palliative care and chronic pain patients receiving methadone and other drugs known to prolong the QTc interval and/or inhibit methadone metabolism in order to develop a risk stratification tool to estimate this risk in this patient population.

Methods:

Patients:

This was a case-control study. Potential subjects were identified through pharmacy records at the University of Rochester Medical Center's (URMC) Strong Memorial and Highland Hospitals between March 14, 2011 and March 14, 2014. Adult inpatients who received methadone for at least one week prior to hospitalization and had an EKG obtained within 2 weeks prior to admission or during the first 24 hours after hospital admission were included. Patients receiving MMT for substance abuse, admitted as a hospice encounter, age < 18 years, or had incomplete medical records were excluded. ECGs included within the patient's electronic medical record were used to determine the presence or absence of QTc interval prolongation. All ECGs were previously reviewed by an attending cardiologist for accuracy. QTc is calculated at URMC using Bazett's correction formula.[10] QTc interval prolongation was defined as QTc interval > 470 msec (males) and > 480 msec (females) or a QTc interval increase > 60 msec from baseline following the definitions from the American Heart Association/American College of Cardiology Foundation (AHA/ACCF) and Food and Drug Administration (FDA).[11,12] The AHA/ACCF definition was selected because it differentiates between genders. The FDA definition of a > 60 msec increase was chosen since it represents a more clinically significant change than > 30 msec.

Patients with a prolonged QTc interval were designated as cases whereas those without QTc interval prolongation were classified as controls. Cases and controls were matched 1:2 according to age range by decade, gender, and history of QTc prolongation.

Procedures:

The following data was obtained from each patient's medical records: age, sex, comorbidities, history of QTc interval prolongation, baseline QTc interval and uncorrected QT interval, heart rate at time of baseline QT/QTc interval, history of structural heart disease (e.g. myocardial infarction, heart failure, valvular disease, or cardiomyopathy), history of bradycardia, history of conduction disorders (e.g. bundle branch block, heart block, arrhythmias, syncope, or long Q-T syndrome), electrolyte abnormalities at the

time of initial inpatient labs (e.g. hypokalemia, hypomagnesemia, or hypocalcemia).[7] Hypokalemia was defined as $K^+ < 3.3$ mEq/L, hypomagnesemia as $Mg^{2+} < 1.3$ mEq/L, and hypocalcemia delineated as a corrected $Ca^{2+} < 8.8$ mg/dL based on our health system's laboratory reference range. The Charlson Comorbidity Index was used to calculate comorbidity scores.[13] Concurrent use of other QTc-prolonging medications as classified by CredibleMeds.org was collected.[14] This website categorizes medications into four classes based on TdP risk (e.g. medications with a known risk of TdP, possible risk of TdP, conditional risk of TdP, and drugs to avoid in congenital long QT). Use of medications that increase serum methadone concentrations such as but not limited to fluconazole, fluoxetine, paroxetine, sertraline, ciprofloxacin, amitriptyline, desipramine, voriconazole were included.[15,16] Methadone indication, scheduled dose, route, frequency, and duration of use at the time of inpatient admission was obtained. Breakthrough methadone doses were not included in the methadone daily dose calculations. One investigator evaluated all the electronic medical records and collected patient data. The study was approved by the URMC institutional review board, and the requirement for informed consent was waived.

Statistical Analyses:

Assuming a prior methadone exposure of 40% in controls, we calculated a sample size of 90 case patients and 180 controls (ratio, 1:2) for the study to have an 80% chance of detecting a clinically meaningful odds ratio of 2.5 between the two groups at the 5% significance level. This was deemed to be clinically significant and necessitate a medication regimen adjustment. We compared the odds of case patients and controls through conditional logistic regression to account for the matching design. Demographic and baseline clinical characteristics between case patients and matched controls were compared using paired t-tests for continuous variables and McNemar's chi-square tests for categorical variables. Variables with a p-value < 0.2 identified in the bivariate analysis were considered as potential confounders in a multivariable conditional logistic regression, using backward and forward stepping. We obtained an adjusted estimate of QTc prolongation by adjusting for covariables that significantly improved the likelihood of the model. Classification and regression tree analysis (CART) was used to identify the

methadone dose associated with QTc prolongation. All reported P values and 95% confidence intervals were two-sided. A P value of less than 0.05 was considered to indicate statistical significance. STATA, version 13.1 (College Station, TX) was used for analyses.

Results:

A total of 908 patients were screened for this study (Figure 1). Two hundred ninety-nine patients were immediately excluded for the following reasons: 190 patients on MMT, 84 patients did not have a documented ECG, and 25 patients were < 18 years. Three hundred ninety-one did not have a prolonged QTc interval, of which 180 patients were included as controls, and 211 patients were excluded for reasons outlined in Figure 1. Two hundred eighteen patients had a prolonged QTc interval. Ninety patients were classified as controls, 103 patients were identified with a prolonged QTc interval while matching case controls and 25 patients did not meet inclusion criteria as detailed in Figure 1.

Table 1 outlines patient demographics. Case patients had a median age of 55 years compared to controls whose median age was 57 years. No case or controls had a previous history of QTc prolongation. Among case and control patients 56.7% were female and 43.3% were male. The mean total Charlson comorbidity score was 4.9 (SD: 3.2) for cases and 4 (SD: 3.1) in controls.   Among cases, methadone was indicated for chronic pain in 69 patients (76.7%), cancer pain in 19 patients (21.1%), and chronic and cancer pain in 2 patients (2.2%). One hundred-fifteen control patients (63.9%) received methadone for chronic pain compared to 52 patients (28.9%) for cancer pain, and chronic and cancer pain in 13 patients (7.2%). The median ME dose was 36.3mg (SD: 27.7mg) in cases (range: 5mg-120mg/day) and 34.6mg (SD: 29.9mg) among controls (range: 5-240mg/day). Cases used ME for a median of 199 days (SD: 302.9 days) prior to study entry and 197 days (SD: 318.3 days) for controls.

Table 2 lists the variables from the univariate analysis included in the conditional multivariate logistic regression model. The final model was tested for collinearity, statistical interactions, and confounding variables. The results of our conditional multivariate logistic regression analysis are included in Table 3.

The most significant variables to predict QTc prolongation in our multivariate conditional logistic regression model were congestive heart failure (CHF) (OR: 11.9; 95% CI: 3.7-38.2; p<0.00), peptic ulcer disease (PUD) (OR: 8.3; 95% CI: 2.4-28.9; p<0.00), hypokalemia (OR: 6.5; 95% CI: 1.5-28.2; p<0.01), rheumatologic diseases (OR: 4.7, 95%: 1.6-13.9; p<0.00), concurrent use of medications with known TdP risk (OR: 4.4; 95% CI: 1.8-10.7; p<0.01), malignancy (OR: 3.3; 95% CI: 1.2-9.3; p<0.03), hypocalemia (OR: 2.1; 95% CI: 0.9-4.8; p<0.07), and ME doses > 45mg/day (OR: 1.9; 95% CI: 0.8-4.8; p<0.16). Mild liver disease decreased patient's QTc prolongation risk (OR: 0.05, 95% CI: 0.0-0.46; p<0.01).

Discussion:

We identified 6 studies in the literature that evaluated methadone's effect on QTc prolongation in PPC patients.[17-22] Three studies identified other risk factors that contributed to ME induced QTc prolongation[17,18,20] Price et al identified increased risk of cardiac events (composite endpoint: QTc > 500 msec, cardiac death, or hospitalization/emergency department visit for a cardiac etiology) in 1246 primary care chronic pain patients with oral ME doses $\geq$ 100mg/day (OR: 6.18; 95% CI: 1.08-35.45) and increasing age (OR: 1.06; 95% CI: 1.03-1.09).[17] Female gender (p=0.0061) and antidepressant use (p=0.0397) were identified as risk factors for a prolonged QTc interval (>450msec) in 90 chronic pain outpatients taking ME compared to controls without ME exposure.[18] Concurrent use of medications associated with QTc prolongation risk, structural heart disease, electrolyte abnormalities, and female gender were found to increase QTc prolongation risk (QTc interval increase >25% from baseline or $\geq$500msec) in 100 palliative care patients receiving ME for cancer pain.[20]   These studies utilized different definitions of QTc interval prolongation, so clinical judgement should be utilized when interpreting findings.

Our final multivariate logistic regression model identified CHF, PUD, hypokalemia, rheumatologic diseases, medications with a known TdP risk, malignancy, hypocalcemia, and ME doses > 45mg/day as potential risk factors and mild liver disease had a protective effect against QTc prolongation in our

chronic pain and palliative care patients. Methadone is most commonly prescribed by a limited number of specialists within our health system who care for PPC patients. Our findings may be influenced by local prescribing patterns and the risk factors we identified in our study may slightly vary when compared to those identified for PPC patients in other geographic areas. The URMC palliative care service frequently collaborates with our institution's advanced heart failure and oncology programs. The large heart failure and oncology programs in our health system may account for the large number of patients with these risk factors in our model. Thirty-two case patients had heart failure compared to 19 control patients and malignancy occurred in 22 case patients versus 18 control patients. Heart failure and hypokalemia are closely related risk factors given the frequent use of loop diuretics in this patient population and were also identified along with hypocalcemia as risk factors by Reddy et al.[20] Rheumatologic diseases were likely a risk factor because lupus nephritis is a common systemic lupus erythematous (SLE) complication and methadone is a preferred opioid in renal insufficiency.[23]   PUD was an unexpected risk factor. Multiple variables may have contributed to this finding, including the potential for increased use of opioids vs. NSAIDs for pain management with this comorbidity or through increased exposure to methadone via inhibition of CYP2C19 with concurrent use of PPIs.[24]

It was expected that concomitant use of medications with a known TdP risk would have an additive effect on QTc prolongation risk given the frequent use of antipsychotics, antiemetics, and antidepressants for mental health comorbidities and symptom management in PPC patients. This was consistent with Reddy et al. findings.[20] We did not assess the impact of dose, actual as needed (e.g. prn) medication utilization, or route of administration in our risk assessment of other QTc prolonging medications. Differences in these risk variables may pose a higher QTc prolongation risk when comparing medication doses or selected routes of administration. For example, 6mg of intravenous haloperiodol has a higher QTc prolongation risk than 2mg of oral haloperidol. Our model did not account for concurrent use of multiple QTc prolonging medications within the same risk class. A patient taking three medications with a known risk of TdP in addition to methadone likely has a higher risk of QTc prolongation than a subject taking

methadone and one medication with a known risk of TdP. Methadone doses > 45mg/day were identified to increase QTc prolongation risk in our model. This dose is lower than the $\geq$ 100mg/day dose that was identified by Price et al. to increase cardiac event risk. It is unclear why mild liver disease decreased QTc prolongation risk in our study cohort. Hypokalemia, hypocalcemia, concurrent use of medications with known TdP risk, and ME doses > 45mg/day are potentially modifiable risks factors. Providers caring for PPC patients should correct or minimize these modifiable risk factors when clinically feasible. Heart failure, PUD, and rheumatologic diseases are less modifiable risk factors in PPC patients given the frequency of advanced stages of chronic illnesses and limited life expectancy in this population.

This study has several additional limitations which may have impacted our findings. Despite having one investigator collect and code all the data, there is still a potential for incomplete or miscoded data. Since many study patients were on ME prior to our health system's electronic medical record implementation or were initiated on methadone by a provider outside of our health system, we did not consistently have baseline ECGs or methadone start dates available for all patients. Bazett's correction formula is not as accurate as the Fridericia's correction formula for tachycardic and bradycardic patients.[12] We utilized the Bazett's correction formula for all study patients which likely resulted in an overcorrected QTc interval in tachycardic patients and an undercorrected QTc interval with bradycardic patients. The small sample size made it difficult to compare various risk factors such as valvular heart disease due to low frequency of occurrence. Cardiac arrest and use of cardioversion were not included in our data collection since many of our palliative care patients had do not resuscitate (DNR) orders.

One variable that we did not assess was the impact of pharmacogenomics. Findings from the MEMORIES trial demonstrated that MMT patients with a CYP2C19*2 gene variant had higher plasma concentrations of methadone's primary metabolite, ethylidene-1, 5-dimethyl-3,3-diphenylpyrrolidene (EDDP) than subjects with the wild type gene (p<0.004).[25] Elevated EDDP levels produced a non-statistically significant increase in the QTc interval from baseline (p=0.1). This pilot study draws attention to the potential influence of CYP2C19 variants on methadone induced QTc interval lengthening.

Our study included a heterogeneous patient cohort of chronic pain and palliative care patients. There are advantages and disadvantages of combining these two patient populations. Palliative care patients often have a shorter life expectancy and more severe symptoms making providers more accepting of a longer QTc interval or less likely to aggressively correct modifiable risk factors because the benefit of methadone for treating refractory pain outweighs the risk of developing TdP. Chronic pain patients have a longer life expectancy, so there is a lower threshold to modify risk factors that increase the QTc interval. However chronic pain and palliative care patient populations are more similar than those in studies that included both chronic pain and MMT patients. This improves the external validity of our findings when assessing which QTc prolongation risk factors are most clinically significant to chronic pain and palliative care patients.

Conclusions:

Predictors of QTc prolongation in our multivariate conditional logistic regression model of this PPC patient cohort included CHF, PUD, hypokalemia, rheumatologic disorders, concurrent use of medications with a known TdP risk, malignancy, hypocalcemia, and ME doses > 45mg/day. PPC patients with these risk factors are at increased risk of developing a prolonged QTc interval while taking methadone. Clinicians caring for these patients should minimize exposure to the identified risk factors and correct modifiable risk factors when clinically feasible. Additional population based studies are needed in larger, more diverse PPC patient cohorts to support these findings.

Acknowledgements:

Author Disclosure Statement:

References:

1.   Mancini I, Lossignol DM, Body JJ: Opioid switch to oral methadone in cancer pain. Curr Opin Oncol. 2000;12:308-313.

2.   Codd EE Shank RP, Schupsky JJ, et al.: Serotonin and norephine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274:1263-1270.

3.   Gorman AL Elliott KJ, Inturrisi CE: The d- and l-isomers of methadone bing to the non-competitive site on the N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1997;223:5-8.

4.   Ebert B Anderson S, Krogsgaard-Larsen P: Ketobemidone, methadone, and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995;187:165-168.

5.   Trinkley KE, Page RL: Medication safety: Implications for cardiovascular health. In: Murphy J, Lee M (eds): Pharmacotherapy Self-Assessment Program, 2013 Book 1. Cardiology and Endocrinology. Lenexa, KS: American College of Clinical Pharmacy, 2013, pp. 205-232.

6. Kao D, Bartelson BB, Khatri V, et al.: Trends in reporting methadone-associated cardiac arrhythmia, 1998-2011. Ann Intern Med. 2013;158:735-740.

7. Gupta A, Lawrence AT, Krishnan K, et al.: Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153:891-899.

8. Zeltser D Justo D, Halkin A, et al.: Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82:282-290.

9. Weimer MB, Chou R: Research gaps on methadone harms and comparative harms: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. J Pain. 2014;15:366-376.

10. Bazett HC: An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-370.

11. Drew BJ, Ackerman MJ, Funk M, et al.: Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121:1047-1060.

12. US Department of Health and Human Services: Food and Drug Administration: Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. In: US Department of Health and Human Services, ed. Rockville, MD: Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2005. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf. Accessed December 5, 2016.

13. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9 CM administrative databases J Clin Epidemiol. 1992;45:613-619.

14. Woosley RL, Romero, KA: www.Crediblemeds.org, QTdrugs list. AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755. Available from: https://www.crediblemeds.org. Accessed December 5, 2016.

15.   Kapur BM, Hutson JR, Chibber T, et al.: Methadone: a review of drug-drug and
       pathophysiological interactions. Crit Rev Clin Lab Sci. 2011;48:171-195.

16.   Weschules DJ, Bain KT, Richeimer S: Actual and potential drug interactions associated with
       methadone. Pain Medicine. 2008;9:315-344.

17.   Price LC, Wobeter B, Delate T, et al.: Methadone for pain and the risk of adverse cardiac
       outcomes. J Pain Symptom Manage. 2014;48:333-342.

18.   Huh B, Park CH: Retrospective analysis of low-dose methadone and QTc prolongation in chronic
       pain patients. Korean J Anesthesiol. 2010;58:338-343.

19.   Reddy S, Fisch M, Bruera E: Oral methadone for cancer pain: no indication of Q-T interval
       prolongation or torsades de pointes. J Pain Symptom Manage. 2004;28:301-303.

20.   Reddy S, Hui D, El Osta B, et al.: The effect of oral methadone on the QTc interval in advanced
       cancer patients: a prospective pilot study. J Palliat Med. 2010;13:33-38.

21.   Fredheim OM, Borchgrevink PC, Hegrenaes L, et al.: Opioid switching from morphine to
       methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-
       month follow-up study. J Pain Symptom Manage. 2006;32:180-185.

22.   Kornick CA, Kilborn MJ, Santiago-Palma J, et al.: QTc interval prolongation associated with
       intravenous methadone. Pain. 2003;105:499-506.

23.   Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28:497-
       504.

24.   Chou R, Cruciana RA, Fiellin DA, et al.: Methadone safety: a clinical practice guideline from the
       American Pain Society and College on Problems of Drug Dependence, in collaboration with the
       Heart Rhythm Society. J Pain. 2014;15:321-337.

25.   Carlquist JF Moody DE, Knight S, et al.: A possible mechanistic link between the CYP2C19
       genotype, the methadone metabolite ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP),
       and methadone-induced corrected QT interval prolongation in a pilot study. Mol Diagn Ther.
       2015;19:131-138.

Table 1. Patient Demographics

Characteristic	Cases n = 90 (%)	Controls n = 180 (%)
Age, y; Median	55	57
Females	51 (56.7)	102 (56.7)
Total Charlson Comorbidity		
Score, Mean (SD)	4.9 (3.2)	4.0 (3.1)
Methadone Indication:		
Chronic Pain	69 (76.7)	115 (63.9)
Cancer Pain	19 (21.1)	52 (28.9)
Chronic and Cancer Pain	2 (2.2)	13 (7.2)
Methadone Rt of Admin:		
Oral	86 (95.6)	170 (94.4)
Feeding Tube (PEG, J-tube)	4 (4.4)	10 (5.6)
Total Oral Methadone Equivalent		
Dose (mg), Mean (SD)	36.3 (27.7)	34.6 (29.9)
Duration of Methadone Use		
Days, Median (SD)	199 (302.9)	197 (318.3)

Table 2. Cases and Controls Univariate Analysis Results

Characteristic	Cases n (%)	Controls n (%)	OR (95% CI)	p
Age, y; Median	55	57	1.1 (0.9 – 1.2)	0.18
Females	51 (56.7%)	102 (56.7%)	1 (0.6 – 1.7)	1.00
Total Charlson Comorbidity Score, Mean (SD)	4.9 (3.2)	4.0 (3.1)	1.1 (1.0 – 1.2)	0.03
Comorbidity				
Myocardial Infarction	7 (7.9)	9 (5)	1.6 (0.6 – 4.2)	0.38
Congestive Heart Failure	32 (35.6)	19 (10.6)	4.9 (2.4 – 9.8)	0.00
Peripheral Vascular Disease	6 (6.7)	13 (7.2)	0.9 (0.3 – 2.5)	0.87
CVD	12 (14.4)	24 (13.3)	1.1 (0.5 – 2.2)	0.81
Dementia	3 (3.3)	4 (2.2)	1.5 (0.3 – 6.7)	0.59
Chronic Pulmonary Disease	33 (36.7)	63 (35)	1.1 (0.6 – 1.9)	0.78
Rheumatologic Disorders	26 (28.9)	17 (9.4)	4.6 (2.1 – 9.9)	0.00
Peptic Ulcer Disease	28 (31.1)	11 (6.1)	11.5 (4.0 –33.1)	0.00
Mild Liver Disease	2 (2.2)	16 (8.9)	0.2 (0.05 – 1.0)	0.05
Diabetes Mellitus	17 (18.9)	37 (20.6)	0.9 (0.5 – 1.7)	0.73
Complications of DM	12 (13.3)	12 (6.7)	2.1 (0.9 – 4.7)	0.08
Plegia	3 (3.3)	9 (5)	0.7 (0.2 – 2.5)	0.54
Renal disease	31 (34.4)	40 (22.2)	1.8 (1.0 – 3.2)	0.04
Malignancy	22 (24.4)	18 (10)	2.8 (1.4 – 5.5)	0.00
Moderate/Severe Liver Dz	11 (12.2)	1 (0.6)	22 (2.8 – 170.4)	0.00
Metastasis – Solid Organ	15 (16.7)	52 (28.9)	0.5 (0.2 – 0.9)	0.03
AIDS	2 (2.2)	7 (3.9)	0.6 (0.1 – 2.8)	0.49
Uncorrected QT Interval, ms Median (SD)	408 (46.3)	372 (46.5)	1.0 (1.0 – 1.0)	0.00
History of Structural Heart Dz:				

Myocardial Infarction	8 (8.9)	8 (4.4)	2 (0.8 – 5.3)	0.17
Heart Failure	32 (35.6)	19 (10.6)	4.9 (2.4 – 9.8)	0.00
Valvular Heart Disease	2 (2.2)	4 (2.2)	1 (0.2 – 5.5)	1.00
Atrial Septal Defect	1 (1.1)	---	---	---
Coronary Artery Disease	18 (20)	21 (11.7)	2.3 (1.0 – 5.1)	0.04
ECG Right or Left				
Ventricular Hypertrophy	19 (21.1)	26 (14.4)	1.6 (0.8 – 3.2)	0.16
History of Conduction Disorders	18 (20)	24 (13.3)	1.6 (0.8 – 3.2)	0.74
History of ECG Disorders	12 (13.3)	33 (18.3)	0.7 (0.3 – 1.4)	0.30
History of Bradycardia	2 (2.2)	12 (6.7)	0.3 (0.1 – 1.4)	0.14
Electrolytes:				
Hypocalcemia	42 (46.7)	58 (32.2)	1.8 (1.1 – 3.1)	0.02
Hypokalemia	12 (13.3)	8 (4.4)	3.2 (1.3 – 8.3)	0.01
Hypomagnesemia	5 (5.6)	7 (3.9)	1.4 (0.5 – 4.5)	0.52
Methadone Inhibitors:	25 (27.8)	29 (16.1)	1.9 (1.1 – 3.5)	0.03
Duration of Methadone Use,				
days; Median (SD)	199 (302.9)	197 (318.3)	1.0 (0.9 – 1.1)	0.81
Frequency of QTc Prolonging				
Medications:				
Zero	6 (6.7)	26 (14.4)	Referent	Referent
1 – 2	35 (38.9)	100 (55.6)	1.7 (0.6 – 4.8)	0.32
3 – 4	37 (41.1)	46 (25.6)	4.5 (1.5 – 13.0)	0.01
5 – 6	8 (8.9)	8 (8.9)	6.8 (1.6 – 30.0)	0.01
> 6	4 (4.4)	---	---	---
Concomitant Medication with:				
Known Risk of TdP	48 (53.3)	51 (28.3)		0.00
Possible Risk of TdP	39 (43.3)	78 (43.3)		1.00

|				
Conditional Risk of TdP	59 (65.6)	95 (52.7)		0.04
Drug to Avoid in Long QT	37 (41.1)	44 (24.4)		0.00
Methadone CART Analysis:				
> 45 mg/day	31 (34.4)	44 (24.4)	1.7 (0.9 – 3.1)	0.07

TdP: torsades de pointes; CART: classification and regression tree analysis; Dz: disease; DM: diabetes mellitus; OR: odds ratio; 95% CI: 95% confidence interval

Table 3. Cases and Controls Multivariate Analysis Results

Characteristic	OR	95% CI	p
Hypokalemia	6.5	1.5 – 28.2	0.01
Concomitant Medication with:			
Known Risk of TdP	4.4	1.8 – 10.7	0.01
Comorbidity:			
Congestive Heart Failure	11.9	3.7 – 38.2	0.00
Rheumatologic Diseases	4.7	1.6 – 13.9	0.00
Peptic Ulcer Disease	8.3	2.4 – 28.9	0.00
Malignancy	3.3	1.2 – 9.3	0.03
Hypocalcemia	2.1	0.9 – 4.8	0.07
Mild Liver Disease	0.05	0.0 – 0.46	0.01
ME CART Analysis (> 45mg/day)	1.9	0.8 – 4.8	0.16

OR = Odds Ratio; CI = Confidence Interval

Figure 1. Patient Screening

908 Patients Screened

299 Excluded:
MMT: 190
No ECG: 84
Pediatric Patients: 25

391 Patients with QTc < 470 msec (males) or < 480 msec (females)

218 Patients with QTc > 470 msec (males) or > 480 msec (females)

180 Case Controls

211 Patients Excluded:
Not on ME > 7 days: 133
Inappropriate ECG timing: 70
Unknown ME start date: 8

90 Cases

103 Potential Study Patients[a]

25 Patients Excluded:
Not on ME > 7 days: 15
Unable to Match Hx QTc prolongation: 2
Unknown ME start date: 1
Inappropriate ECG timing: 6

[a] = Patients with QTc > 470 msec (males) or QTc > 480 msec (females) who were identified while matching case controls; ME = methadone, MMT = methadone maintenance therapy